JP MORGAN/CALL/ELI LILLY & CO/1300/0.01/16.01.26 | Market Closed - Börse Stuttgart 09:50:52 24/05/2024 BST | ||
| 0.44 EUR | -2.22% |
|
| Current month | +62.96% | ||
| 1 month | +41.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 0.44 | -2.22% |
| 23/05/24 | 0.45 | +4.65% |
| 22/05/24 | 0.43 | +16.22% |
| 21/05/24 | 0.37 | +8.82% |
| 20/05/24 | 0.34 | -2.86% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 09:50 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK7RM3 |
| ISIN | DE000JK7RM37 |
| Date issued | 10/04/2024 |
| Strike | 1,300 $ |
| Maturity | 16/01/2026 (602 Days) |
| Parity | 100 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.45 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.03 € |
| Spread % | 6.52% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- Warrant
